The emerging issue of novel psychoactive substances (NPS), often dubbed "designer drugs," presents a significant challenge to global public health and law enforcement. These substances, frequently manufactured to circumvent existing drug laws, quickly appear on the market and are marketed as "legal highs" or "research chemicals," attracting individ